Genetics of Immune Dysregulation and Cancer Predisposition: Two Sides of the Same Coin
Open Access
- 27 September 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 210 (2), 114-127
- https://doi.org/10.1093/cei/uxac089
Abstract
Approximately 10% of cancers have a hereditary predisposition. However, no genetic diagnosis is available in 60%-80% of familial cancers. In some of these families, immune dysregulation-mediated disease is frequent. The immune system plays a critical role in identifying and eliminating tumors; thus, dysregulation of the immune system can increase the risk of developing cancer. This review focuses on some of the genes involved in immune dysregulation the promote the risk for cancer. Genetic counseling for patients with cancer currently focuses on known genes that raise the risk of cancer. In missing hereditary familial cases, the history family of immune dysregulation should be recorded, and genes related to the immune system should be analyzed in relevant families. On the other hand, patients with immune disorders diagnosed with a pathogenic mutation in an immune regulatory gene may have an increased risk of cancer. Therefore, those patients need to be under surveillance for cancer. Gene panel and exome sequencing are currently standard methods for genetic diagnosis, providing an excellent opportunity to jointly test cancer and immune genes.This publication has 121 references indexed in Scilit:
- The STAT5b Pathway Defect and AutoimmunityFrontiers in Immunology, 2012
- The JAK2 V617F somatic mutation, mortality and cancer risk in the general populationHaematologica, 2010
- The Many Roles of FAS Receptor Signaling in the Immune SystemImmunity, 2009
- Role of JAK2 in the pathogenesis and therapy of myeloproliferative disordersNature Reviews Cancer, 2007
- Induction of autoimmune disease in CTLA-4−/−mice depends on a specific CD28 motif that is required forin vivocostimulationProceedings of the National Academy of Sciences of the United States of America, 2007
- High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosisBritish Journal of Cancer, 2007
- Immune surveillance of tumorsJCI Insight, 2007
- Cancer immunoediting from immune surveillance to immune escapeImmunology, 2007
- Nuclear factor-κB in cancer development and progressionNature, 2006
- NF-κB: linking inflammation and immunity to cancer development and progressionNature Reviews Immunology, 2005